Collaborations, Opportunities at Annual ASCO Conference
By Karen Gehrman | cancer.ucsf.edu | June 14, 2018
Once again UCSF had an impressive presence at this year's annual meeting of the American Society of Clinical Oncologists (ASCO) in Chicago. One of the world’s most prestigious gatherings of oncology professionals, ASCO 2018 drew more than 40,000 cancer experts focusing on groundbreaking research and advances in cancer with the theme of Delivering Discoveries: Expanding the Reach of Precision Medicine.
Honors and Awards
- Tim Ferng, MD, a fellow in the Smith lab, and Lauren Levine, MD, a fellow in the Spitzer lab, were among 72 young researchers from across the US and Canada to receive 2018 Young Investigator Awards from ASCO’s Conquer Cancer Foundation..
- Laura Esserman, MD, MBA was one of 21 cancer researchers acknowledged with a Giants of Cancer Care Award by OncLive.
ASCO provides investigators of all levels a chance to present and review research, confer with colleagues, and return with new ideas. In addition to attending keynotes, oral abstract presentations, posters presentations, and a variety of special events, attendees discuss and debate over social media.
Twitter usage at ASCO has grown dramatically since 2011, demonstrating the increasing role of social media in the dissemination of findings at conferences.
Over 17,000 individual accounts posted over 80,000 tweets, with the hashtag #ASCO18 during the conference. That averaged 5 tweets per participant, and an average overall of almost 600 per hour. Many investigators, such as Dr. Hope Rugo, used Twitter to confer with colleagues on research findings and treatment recommendations in real time during presentations.
Online news channels such as @onclive, @oncologytube, and @ascopost conducted interviews with industry experts specifically for distribution on social media due to the large volume of traffic.
A new addition to the annual meeting, the ASCO Voices presentation was an informal, innovative, non-competitive session of individuals presentating a variety of perspectives to expand the view of oncology, medicine, and the world.
Nina Shah, MD discussed her personal experience on being a mentor with colleague Rachna T. Shroff, MD of the University of Arizona.
Junior Investigators Represent the HDFCCC
First author Claire Hooker discussed work with Emily Bergsland, MD on "Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas."
Veteran Members Share Leading ScienceWe caught a few of our members between sessions to share their thoughts. Pam Munster commented on her research on how to boost immune response for patients with hormone therapy resistant breast cancer, while Nina Shah remarked on the surprising benefits of organizations like ASCO such as collaborations and unexpected funding opportunities.
For more detail on presentations by HDFCCC members, download the report.